Cancer-targeting chimeric antigen receptors

Genetically modified effector cells with multi-antigen targeting CARs address CRS and toxicity issues, improving persistence and efficacy in cancer therapy by using human antibodies and multiple antigen-specific domains.

JP2026035690APending Publication Date: 2026-03-04UNIV OF SOUTHERN CALIFORNIA
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2025-11-26
Publication Date
2026-03-04

AI Technical Summary

Technical Problem

Current CAR (Chimeric Antigen Receptor) therapies for cancer treatment face challenges such as cytokine release syndrome (CRS), toxicity due to non-physiological signaling, and limited persistence and efficacy due to antigen-independent activation and immune exhaustion, particularly in targeting antigens expressed at low levels by normal tissues.

Method used

Development of genetically modified effector cells, such as T cells and NK cells, equipped with chimeric antigen receptors (CARs) that incorporate multiple antigen-specific domains and costimulatory signals, utilizing human or humanized antibodies to enhance persistence and reduce toxicity, and targeting multiple antigens/epitopes to generate polyclonal immune responses.

Benefits of technology

The modified CARs improve long-term persistence and reduce toxicity, enhancing therapeutic efficacy against cancer and other diseases by inducing robust and controlled immune responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026035690000001_ABST
    Figure 2026035690000001_ABST
Patent Text Reader

Abstract

Provided are genetically modified effector cells comprising a polynucleotide encoding a chimeric antigen receptor for treating cancer, and compositions comprising the cells. [Solution] Compositions are provided, comprising cells containing nucleic acids encoding a chimeric antigen receptor (CAR) and one or more signaling proteins selected from K13-vFLIP, MC159-vFLIP, cFLIP-L, cFLIP-p22, HTLV1-Tax, and HTLV2-Tax, wherein the CAR comprises: a) an extracellular antigen-specific domain; b) a transmembrane domain; and c) an intracellular signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM); c) is located at the C-terminus of the chimeric receptor. In some embodiments, the CAR further comprises one or more costimulatory domains. Methods for treating diseases using the compositions are also provided.
Need to check novelty before this filing date? Find Prior Art